Application of CRISPR/Cas9 System in the Treatment of Alzheimer's Disease and Neurodegenerative Diseases.
APOE
Alzheimer’s disease
Amyloid plaques
CRISPR/Cas9
Neurodegenerative diseases
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
19 Apr 2024
19 Apr 2024
Historique:
received:
17
10
2023
accepted:
21
03
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
19
4
2024
Statut:
aheadofprint
Résumé
Alzheimer's, Parkinson's, and Huntington's are some of the most common neurological disorders, which affect millions of people worldwide. Although there have been many treatments for these diseases, there are still no effective treatments to treat or completely stop these disorders. Perhaps the lack of proper treatment for these diseases can be related to various reasons, but the poor results related to recent clinical research also prompted doctors to look for new treatment approaches. In this regard, various researchers from all over the world have provided many new treatments, one of which is CRISPR/Cas9. Today, the CRISPR/Cas9 system is mostly used for genetic modifications in various species. In addition, by using the abilities available in the CRISPR/Cas9 system, researchers can either remove or modify DNA sequences, which in this way can establish a suitable and useful treatment method for the treatment of genetic diseases that have undergone mutations. We conducted a non-systematic review of articles and study results from various databases, including PubMed, Medline, Web of Science, and Scopus, in recent years. and have investigated new treatment methods in neurodegenerative diseases with a focus on Alzheimer's disease. Then, in the following sections, the treatment methods were classified into three groups: anti-tau, anti-amyloid, and anti-APOE regimens. Finally, we discussed various applications of the CRISPR/Cas-9 system in Alzheimer's disease. Today, using CRISPR/Cas-9 technology, scientists create Alzheimer's disease models that have a more realistic phenotype and reveal the processes of pathogenesis; following the screening of defective genes, they establish treatments for this disease.
Identifiants
pubmed: 38639864
doi: 10.1007/s12035-024-04143-2
pii: 10.1007/s12035-024-04143-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Gitler AD, Dhillon P, Shorter J (2017) Neurodegenerative disease: models, mechanisms, and new hope. Dis Model Mech 10(5):499–502
pubmed: 28468935
pmcid: 5451177
doi: 10.1242/dmm.030205
Checkoway H, Lundin JI, Kelada SN (2011) Neurodegenerative diseases. IARC Sci Publ 163:407–419
Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I (2023) Hallmarks of neurodegenerative diseases. Cell. 186(4):693–714
pubmed: 36803602
doi: 10.1016/j.cell.2022.12.032
Gan L, Cookson MR, Petrucelli L, La Spada AR (2018) Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci 21(10):1300–1309
pubmed: 30258237
pmcid: 6278826
doi: 10.1038/s41593-018-0237-7
Kumar A, Sidhu J, Goyal A, Tsao JW (2023) Alzheimer Disease. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Jaskirat Sidhu declares no relevant financial relationships with ineligible companies. Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies. In: Disclosure: Jack Tsao declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright © 2023. StatPearls Publishing LLC
Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MG (2019) Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci 26(1):33
pubmed: 31072403
pmcid: 6507104
doi: 10.1186/s12929-019-0524-y
DeMaagd G, Philip A (2015) Parkinson's disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P & T : a Peer-Rev J Formula Manag 40(8):504–532
McColgan P, Tabrizi SJ (2018) Huntington's disease: a clinical review. Eur J Neurol 25(1):24–34
pubmed: 28817209
doi: 10.1111/ene.13413
Roos RAC (2010) Huntington's disease: a clinical review. Orphanet J Rare Dis 5(1):40
pubmed: 21171977
pmcid: 3022767
doi: 10.1186/1750-1172-5-40
Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27(10):1918–1929
pubmed: 32526057
pmcid: 7540334
doi: 10.1111/ene.14393
Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL et al (2019) Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 15(10):565–581
pubmed: 31501588
doi: 10.1038/s41582-019-0244-7
Cascione M, De Matteis V, Leporatti S, Rinaldi R (2020) The new frontiers in neurodegenerative diseases treatment: liposomal-based strategies. Front Bioeng Biotechnol 8:566767
pubmed: 33195128
pmcid: 7649361
doi: 10.3389/fbioe.2020.566767
Lipton SA (2004) Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRX 1(1):101–110
pubmed: 15717010
pmcid: 534915
doi: 10.1602/neurorx.1.1.101
Hallett PJ, Standaert DG (2004) Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 102(2):155–174
pubmed: 15163596
doi: 10.1016/j.pharmthera.2004.04.001
Luo D, Reith M, Dutta AK (2020) Chapter 26 - dopamine agonists in treatment of Parkinson's disease: an overview. In: Martin CR, Preedy VR (eds) Diagnosis and Management in Parkinson's Disease. Academic Press, pp. 445–460
doi: 10.1016/B978-0-12-815946-0.00026-0
Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. Jama 323(6):548–560
pubmed: 32044947
doi: 10.1001/jama.2019.22360
Caraci F, Santagati M, Caruso G, Cannavò D, Leggio GM, Salomone S et al (2020) New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin. F1000Res 9. https://doi.org/10.12688/f1000research.22662.1
Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L et al (2022) Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond. Transl Neurodegen 11(1):18
doi: 10.1186/s40035-022-00292-3
Sudhakar V, Richardson RM (2019) Gene therapy for neurodegenerative diseases. Neurotherapeutics 16(1):166–175
pubmed: 30542906
doi: 10.1007/s13311-018-00694-0
Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J (2022) A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci 23(3):1851
pubmed: 35163773
pmcid: 8837071
doi: 10.3390/ijms23031851
Afzal SM, Vafa A, Rashid S, Barnwal P, Shahid A, Shree A et al (2021) Protective effect of hesperidin against N, N′-dimethylhydrazine induced oxidative stress, inflammation, and apoptotic response in the colon of Wistar rats. Environ Toxicol 36(4):642–653
doi: 10.1002/tox.23068
Breijyeh Z, Karaman R (2020) Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules 25(24):5789
pubmed: 33302541
pmcid: 7764106
doi: 10.3390/molecules25245789
Czapiewski S, Brown-Nyseth V (2016) Syndromes of brain dysfunction presenting with cognitive impairment or behavioral disturbance: delirium, dementia, and mental disorders due to another medical condition. The Med Basis Psychiatr:17–41
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S et al (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396(10248):413–446
pubmed: 32738937
pmcid: 7392084
doi: 10.1016/S0140-6736(20)30367-6
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1(1):a006189
pubmed: 22229116
pmcid: 3234452
doi: 10.1101/cshperspect.a006189
Khanahmadi M, Farhud DD, Malmir M (2015) Genetic of Alzheimer’s disease: a narrative review article. Iran J Public Health 44(7):892
pubmed: 26576367
pmcid: 4645760
Wen K-x, Milic J, El-Khodor B, Dhana K, Nano J, Pulido T et al (2016) The role of DNA methylation and histone modifications in neurodegenerative diseases: a systematic review. Plos One 11(12):e0167201
pubmed: 27973581
pmcid: 5156363
doi: 10.1371/journal.pone.0167201
Zhao L, Woody SK, Chhibber A (2015) Estrogen receptor β in Alzheimer’s disease: from mechanisms to therapeutics. Ageing Res Rev 24:178–190
pubmed: 26307455
pmcid: 4661108
doi: 10.1016/j.arr.2015.08.001
Hu N, Yu J-T, Tan L, Wang Y-L, Sun L, Tan L (2013) Nutrition and the risk of Alzheimer's disease. Biomed Res Int 2013. https://doi.org/10.1155/2013/524820
Adlard PA, Bush AI (2006) Metals and Alzheimer's disease. J Alzheimers Dis 10(2-3):145–163
pubmed: 17119284
doi: 10.3233/JAD-2006-102-303
Baglietto-Vargas D, Shi J, Yaeger DM, Ager R, LaFerla FM (2016) Diabetes and Alzheimer’s disease crosstalk. Neurosci Biobehav Rev 64:272–287
pubmed: 26969101
doi: 10.1016/j.neubiorev.2016.03.005
de Toledo Ferraz Alves TC, Ferreira LK, Wajngarten M, Busatto GF (2010) Cardiac disorders as risk factors for Alzheimer's disease. J Alzheimers Dis 20(3):749–763
pubmed: 20413875
doi: 10.3233/JAD-2010-091561
Turner RS, Stubbs T, Davies DA, Albensi BC (2020) Potential new approaches for diagnosis of Alzheimer's disease and related dementias. Front Neurol 11:496
pubmed: 32582013
pmcid: 7290039
doi: 10.3389/fneur.2020.00496
Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med 284(6):643–663
pubmed: 30051512
doi: 10.1111/joim.12816
Vaz M, Silvestre S (2020) Alzheimer's disease: recent treatment strategies. Eur J Pharmacol 887:173554
pubmed: 32941929
doi: 10.1016/j.ejphar.2020.173554
Hanafy AS, Schoch S, Lamprecht A (2020) CRISPR/CAS9 delivery potentials in Alzheimer’s disease management: a mini review. Pharmaceutics 12(9):801
pubmed: 32854251
pmcid: 7559557
doi: 10.3390/pharmaceutics12090801
Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B et al (2018) Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med 378(18):1691–1703
pubmed: 29719179
pmcid: 6776074
doi: 10.1056/NEJMoa1706441
Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL et al (2019) Randomized trial of verubecestat for prodromal Alzheimer’s disease. N Engl J Med 380(15):1408–1420
pubmed: 30970186
pmcid: 6776078
doi: 10.1056/NEJMoa1812840
Cummings J, Lee G, Ritter A, Zhong K (2018) Alzheimer's disease drug development pipeline: 2018. Alzheimer's & Dementia 4:195–214
doi: 10.1016/j.trci.2018.03.009
Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA et al (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. Jama 302(23):2557–2564
pubmed: 20009055
pmcid: 2902875
doi: 10.1001/jama.2009.1866
Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M et al (2015) Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol 72(11):1324–1333
pubmed: 26414022
doi: 10.1001/jamaneurol.2015.0607
Sampson EL, Jenagaratnam L, McShane R (2014) Metal protein attenuating compounds for the treatment of Alzheimer's dementia. Cochrane Database Syst Rev 2. https://doi.org/10.1002/14651858.CD005380.pub5
Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L et al (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60(12):1685–1691
pubmed: 14676042
doi: 10.1001/archneur.60.12.1685
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J et al (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. The Lancet Neurol 7(9):779–786
pubmed: 18672400
doi: 10.1016/S1474-4422(08)70167-4
Pagano K, Tomaselli S, Molinari H, Ragona L (2020) Natural compounds as inhibitors of Aβ peptide aggregation: chemical requirements and molecular mechanisms. Front Neurosci 14:619667
pubmed: 33414705
pmcid: 7783407
doi: 10.3389/fnins.2020.619667
Mantile F, Prisco A (2020) Vaccination against β-amyloid as a strategy for the prevention of Alzheimer’s disease. Biology 9(12):425
pubmed: 33260956
pmcid: 7761159
doi: 10.3390/biology9120425
Pillai R, Uyehara-Lock JH, Bellinger FP (2014) Selenium and selenoprotein function in brain disorders. IUBMB Life 66(4):229–239
pubmed: 24668686
doi: 10.1002/iub.1262
Khalil HS, Mitev V, Vlaykova T, Cavicchi L, Zhelev N (2015) Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. J Biotechnol 202:40–49
pubmed: 25747275
doi: 10.1016/j.jbiotec.2015.02.032
Leggio GM, Catania MV, Puzzo D, Spatuzza M, Pellitteri R, Gulisano W et al (2016) The antineoplastic drug flavopiridol reverses memory impairment induced by amyloid-ß1-42 oligomers in mice. Pharmacol Res 106:10–20
pubmed: 26875816
doi: 10.1016/j.phrs.2016.02.007
Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz H-J et al (2015) A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis 45(1):75–88
pubmed: 25537011
doi: 10.3233/JAD-141959
Andrade Nunes M, Araujo Viel T, Sousa BH (2013) Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res 10(1):104–107
Matsunaga S, Fujishiro H, Takechi H (2019) Efficacy and safety of glycogen synthase kinase 3 inhibitors for Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 69(4):1031–1039
pubmed: 31156177
doi: 10.3233/JAD-190256
Yu T-W, Lane H-Y, Lin C-H (2021) Novel therapeutic approaches for Alzheimer’s disease: an updated review. Int J Mol Sci 22(15):8208
pubmed: 34360973
pmcid: 8348485
doi: 10.3390/ijms22158208
Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey J et al (2015) Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis 44(2):705–720
pubmed: 25550228
doi: 10.3233/JAD-142874
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH et al (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388(10062):2873–2884
pubmed: 27863809
pmcid: 5164296
doi: 10.1016/S0140-6736(16)31275-2
Cox KH, Pipingas A, Scholey AB (2015) Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol 29(5):642–651
pubmed: 25277322
doi: 10.1177/0269881114552744
Gozes I (2011) Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des 17(31):3413–3417
pubmed: 21902667
doi: 10.2174/138161211798072553
Morimoto BH, Fox AW, Stewart AJ, Gold M (2013) Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases. Expert Rev Clin Pharmacol 6(5):483–502
pubmed: 23971871
doi: 10.1586/17512433.2013.827403
Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J et al (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55(11):2325–2333
pubmed: 7757983
Fitzgerald DP, Emerson DL, Qian Y, Anwar T, Liewehr DJ, Steinberg SM et al (2012) TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther 11(9):1959–1967
pubmed: 22622283
pmcid: 7489285
doi: 10.1158/1535-7163.MCT-12-0061
Zumbar CT, Usubalieva A, King PD, Li X, Mifsud CS, Dalton HM et al (2018) The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells. J Neuro-Oncol 137:481–492
doi: 10.1007/s11060-018-2755-2
Gozes I (2011) NAP (davunetide) provides functional and structural neuroprotection. Curr Pharm Des 17(10):1040–1044
pubmed: 21524250
doi: 10.2174/138161211795589373
Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A et al (2016) Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy. Immunotherapy 8(9):1119–1134
pubmed: 27485083
doi: 10.2217/imt-2016-0019
Novak P, Zilka N, Zilkova M, Kovacech B, Skrabana R, Ondrus M et al (2019) AADvac1, an active immunotherapy for Alzheimer’s disease and non Alzheimer tauopathies: an overview of preclinical and clinical development. J Prev Alzheimers Dis 6:63–69
pubmed: 30569088
Theunis C, Crespo-Biel N, Gafner V, Pihlgren M, López-Deber MP, Reis P et al (2013) Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy. PloS one 8(8):e72301
pubmed: 23977276
pmcid: 3747157
doi: 10.1371/journal.pone.0072301
Hoskin JL, Sabbagh MN, Al-Hasan Y, Decourt B (2019) Tau immunotherapies for Alzheimer’s disease. Expert Opin Investig Drugs 28(6):545–554
pubmed: 31094578
pmcid: 7169377
doi: 10.1080/13543784.2019.1619694
Qureshi IA, Tirucherai G, Ahlijanian MK, Kolaitis G, Bechtold C, Grundman M (2018) A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimer's & Dementia 4:746–755
doi: 10.1016/j.trci.2018.10.007
Cao J, Hou J, Ping J, Cai D (2018) Advances in developing novel therapeutic strategies for Alzheimer’s disease. Mol Neurodegener 13:1–20
doi: 10.1186/s13024-018-0299-8
Boehm-Cagan A, Bar R, Liraz O, Bielicki JK, Johansson JO, Michaelson DM (2016) ABCA1 agonist reverses the ApoE4-driven cognitive and brain pathologies. J Alzheimers Dis 54(3):1219–1233
pubmed: 27567858
doi: 10.3233/JAD-160467
Santos DB, Peres KC, Ribeiro RP, Colle D, dos Santos AA, Moreira EL et al (2012) Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice. Exp Neurol 233(2):767–775
pubmed: 22173317
doi: 10.1016/j.expneurol.2011.11.036
Krishnamurthy K, Cantillana V, Wang H, Sullivan PM, Kolls BJ, Ge X et al (2020) ApoE mimetic improves pathology and memory in a model of Alzheimer’s disease. Brain Res 1733:146685
pubmed: 32007397
doi: 10.1016/j.brainres.2020.146685
Serrano-Pozo A, Das S, Hyman BT (2021) APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. The Lancet Neurology 20(1):68–80
pubmed: 33340485
pmcid: 8096522
doi: 10.1016/S1474-4422(20)30412-9
Miranda A, Montiel E, Ulrich H, Paz C (2021) Selective secretase targeting for Alzheimer’s disease therapy. J Alzheimers Dis 81(1):1–17
pubmed: 33749645
doi: 10.3233/JAD-201027
Panza F, Lozupone M, Watling M, Imbimbo BP (2019) Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease? Expert Rev Neurother 19(7):599–602
pubmed: 31112433
doi: 10.1080/14737175.2019.1621751
Huang L-K, Chao S-P, Hu C-J (2020) Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 27(1):1–13
doi: 10.1186/s12929-019-0609-7
Uddin MS, Hossain MF, Al Mamun A, Shah MA, Hasana S, Bulbul IJ et al (2020) Exploring the multimodal role of phytochemicals in the modulation of cellular signaling pathways to combat age-related neurodegeneration. Sci Total Environ 725:138313
pubmed: 32464743
doi: 10.1016/j.scitotenv.2020.138313
Mahase E (2021) Three FDA advisory panel members resign over approval of Alzheimer’s drug. British Medical Journal Publishing Group
doi: 10.1136/bmj.n1503
Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M (2020) Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res Ther 12:1–10
doi: 10.1186/s13195-020-00663-w
Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2(10):a006296
pubmed: 23028126
pmcid: 3475404
doi: 10.1101/cshperspect.a006296
Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A et al (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118(2):671–682
pubmed: 18202749
pmcid: 2200302
Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM et al (2005) Deletion of Abca1 increases Aβ deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280(52):43236–43242
pubmed: 16207708
doi: 10.1074/jbc.M508780200
Champagne D, Pearson D, Dea D, Rochford J, Poirier J (2003) The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer’s disease. Neuroscience 121(1):99–110
pubmed: 12946703
doi: 10.1016/S0306-4522(03)00361-0
Kuszczyk MA, Sanchez S, Pankiewicz J, Kim J, Duszczyk M, Guridi M et al (2013) Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration. Am J Pathol 182(5):1750–1768
pubmed: 23499462
pmcid: 3644726
doi: 10.1016/j.ajpath.2013.01.034
Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM et al (2000) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47(6):739–747
pubmed: 10852539
doi: 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8
Ulrich JD, Ulland TK, Mahan TE, Nyström S, Nilsson KP, Song WM et al (2018) ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med 215(4):1047–1058
pubmed: 29483128
pmcid: 5881464
doi: 10.1084/jem.20171265
Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V et al (2009) Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular Aβ clearance. Neuron 64(5):632–644
pubmed: 20005821
pmcid: 2787195
doi: 10.1016/j.neuron.2009.11.013
Huynh T-PV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H et al (2017) Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of β-amyloidosis. Neuron 96(5):1013–23. e4
pubmed: 29216448
pmcid: 5728673
doi: 10.1016/j.neuron.2017.11.014
Lin Y-T, Seo J, Gao F, Feldman HM, Wen H-L, Penney J et al (2018) APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron 98(6):1141–54.e7
pubmed: 29861287
pmcid: 6023751
doi: 10.1016/j.neuron.2018.05.008
Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T et al (2013) Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 5(212):212ra161
pubmed: 24259049
pmcid: 4334150
doi: 10.1126/scitranslmed.3007000
Soeda Y, Takashima A (2020) New insights into drug discovery targeting tau protein. Front Mol Neurosci 13:590896
pubmed: 33343298
pmcid: 7744460
doi: 10.3389/fnmol.2020.590896
Chandrasegaran S, Carroll D (2016) Origins of programmable nucleases for genome engineering. J Mol Biol 428(5):963–989
pubmed: 26506267
doi: 10.1016/j.jmb.2015.10.014
Doudna JA, Charpentier E (2014) The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096
pubmed: 25430774
doi: 10.1126/science.1258096
Hu JH, Davis KM, Liu DR (2016) Chemical biology approaches to genome editing: understanding, controlling, and delivering programmable nucleases. Cell Chem Biol 23(1):57–73
pubmed: 26933736
doi: 10.1016/j.chembiol.2015.12.009
Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6):1262–1278
pubmed: 24906146
pmcid: 4343198
doi: 10.1016/j.cell.2014.05.010
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N et al (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819–823
pubmed: 23287718
pmcid: 3795411
doi: 10.1126/science.1231143
Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M et al (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32(6):551–553
pubmed: 24681508
pmcid: 4157757
doi: 10.1038/nbt.2884
Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z et al (2015) CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6(5):363–372
pubmed: 25894090
pmcid: 4417674
doi: 10.1007/s13238-015-0153-5
Schwank G, Koo B-K, Sasselli V, Dekkers JF, Heo I, Demircan T et al (2013) Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13(6):653–658
pubmed: 24315439
doi: 10.1016/j.stem.2013.11.002
Tabebordbar M, Zhu K, Cheng JK, Chew WL, Widrick JJ, Yan WX et al (2016) In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351(6271):407–411
pubmed: 26721686
doi: 10.1126/science.aad5177
Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RMC et al (2016) In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351(6271):403–407
pubmed: 26721684
doi: 10.1126/science.aad5143
Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN (2014) Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA. Science 345(6201):1184–1188
pubmed: 25123483
pmcid: 4398027
doi: 10.1126/science.1254445
Wojtal D, Kemaladewi DU, Malam Z, Abdullah S, Wong TW, Hyatt E et al (2016) Spell checking nature: versatility of CRISPR/Cas9 for developing treatments for inherited disorders. Am J Hum Genet 98(1):90–101
pubmed: 26686765
doi: 10.1016/j.ajhg.2015.11.012
Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O et al (2015) BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527(7577):192–197
pubmed: 26375006
pmcid: 4644101
doi: 10.1038/nature15521
Rabinowitz R, Kadair A, Ben-Zur T, Michaelson D, Offen D (2019) ApoE4 allele specific knockout using a synthetic Cas9 variant as a potential gene therapy approach for Alzheimer's disease. Cytotherapy 21(5):e7
doi: 10.1016/j.jcyt.2019.04.022
Sharma G, Sharma AR, Bhattacharya M, Lee SS, Chakraborty C (2021) CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases. Mol Ther 29(2):571–586
pubmed: 33238136
doi: 10.1016/j.ymthe.2020.09.028
Heler R, Samai P, Modell JW, Weiner C, Goldberg GW, Bikard D et al (2015) Cas9 specifies functional viral targets during CRISPR-Cas adaptation. Nature 519(7542):199–202
pubmed: 25707807
pmcid: 4385744
doi: 10.1038/nature14245
Szczelkun MD, Tikhomirova MS, Sinkunas T, Gasiunas G, Karvelis T, Pschera P et al (2014) Direct observation of R-loop formation by single RNA-guided Cas9 and cascade effector complexes. Proc Natl Acad Sci USA 111(27):9798–9803
pubmed: 24912165
pmcid: 4103346
doi: 10.1073/pnas.1402597111
Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA (2014) DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507(7490):62–67
pubmed: 24476820
pmcid: 4106473
doi: 10.1038/nature13011
Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA et al (2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471(7340):602–607
pubmed: 21455174
pmcid: 3070239
doi: 10.1038/nature09886
Gasiunas G, Barrangou R, Horvath P, Siksnys V (2012) Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 109(39):E2579–E2586
pubmed: 22949671
pmcid: 3465414
doi: 10.1073/pnas.1208507109
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816–821
pubmed: 22745249
pmcid: 6286148
doi: 10.1126/science.1225829
Barrangou R, Horvath P (2017) A decade of discovery: CRISPR functions and applications. Nat Microbiol 2:17092
pubmed: 28581505
doi: 10.1038/nmicrobiol.2017.92
Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP et al (2021) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 184(3):844
pubmed: 33545038
doi: 10.1016/j.cell.2021.01.019
Anton T, Karg E, Bultmann S (2018) Applications of the CRISPR/Cas system beyond gene editing. Biol Methods Protoc 3(1):bpy002
pubmed: 32161796
pmcid: 6994046
doi: 10.1093/biomethods/bpy002
Heidenreich M, Zhang F (2016) Applications of CRISPR-Cas systems in neuroscience. Nat Rev Neurosci 17(1):36–44
pubmed: 26656253
doi: 10.1038/nrn.2015.2
Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE et al (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154(6):1380–1389
pubmed: 23992846
pmcid: 3856256
doi: 10.1016/j.cell.2013.08.021
Zheng Y, Li J, Wang B, Han J, Hao Y, Wang S et al (2020) Endogenous type I CRISPR-Cas: from foreign DNA defense to prokaryotic engineering. Front Bioeng Biotechnol 8:62
pubmed: 32195227
pmcid: 7064716
doi: 10.3389/fbioe.2020.00062
Doudna JA, Gersbach CA (2015) Genome editing: the end of the beginning. Genome Biol 16:292
pubmed: 26700220
pmcid: 4699356
doi: 10.1186/s13059-015-0860-5
Cox DB, Platt RJ, Zhang F (2015) Therapeutic genome editing: prospects and challenges. Nat Med 21(2):121–131
pubmed: 25654603
pmcid: 4492683
doi: 10.1038/nm.3793
Liu C, Zhang L, Liu H, Cheng K (2017) Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release 266:17–26
pubmed: 28911805
pmcid: 5723556
doi: 10.1016/j.jconrel.2017.09.012
Wu Z, Yang H, Colosi P (2010) Effect of genome size on AAV vector packaging. Mol Ther 18(1):80–86
pubmed: 19904234
doi: 10.1038/mt.2009.255
Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32(4):347–355
pubmed: 24584096
pmcid: 4022601
doi: 10.1038/nbt.2842
Tsai SQ, Joung JK (2016) Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat Rev Genet 17(5):300–312
pubmed: 27087594
pmcid: 7225572
doi: 10.1038/nrg.2016.28
Kuscu C, Arslan S, Singh R, Thorpe J, Adli M (2014) Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol 32(7):677–683
pubmed: 24837660
doi: 10.1038/nbt.2916
Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH (2015) Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol Ther Nucleic Acids 4(11):e264
pubmed: 26575098
pmcid: 4877446
doi: 10.1038/mtna.2015.37
Haeussler M, Schönig K, Eckert H, Eschstruth A, Mianné J, Renaud JB et al (2016) Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol 17(1):148
pubmed: 27380939
pmcid: 4934014
doi: 10.1186/s13059-016-1012-2
Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J (2015) Don’t edit the human germ line. Nature 519(7544):410–411
pubmed: 25810189
doi: 10.1038/519410a
Isasi R, Kleiderman E, Knoppers BM (2016) Genetic technology regulation. Editing policy to fit the genome? Science 351(6271):337–339
pubmed: 26797999
doi: 10.1126/science.aad6778
De Plano LM, Calabrese G, Conoci S, Guglielmino SPP, Oddo S, Caccamo A (2022) Applications of CRISPR-Cas9 in Alzheimer's disease and related disorders. Int J Mol Sci 23(15):8714
pubmed: 35955847
pmcid: 9368966
doi: 10.3390/ijms23158714
Lu L, Yu X, Cai Y, Sun M, Yang H (2021) Application of CRISPR/Cas9 in Alzheimer's disease. Front Neurosci 15:803894
pubmed: 34992519
pmcid: 8724030
doi: 10.3389/fnins.2021.803894
Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362(4):329–344
pubmed: 20107219
doi: 10.1056/NEJMra0909142
Bhardwaj S, Kesari KK, Rachamalla M, Mani S, Ashraf GM, Jha SK et al (2022) CRISPR/Cas9 gene editing: new hope for Alzheimer's disease therapeutics. J Adv Res 40:207–221
pubmed: 36100328
doi: 10.1016/j.jare.2021.07.001
Bettens K, Sleegers K, Van Broeckhoven C (2013) Genetic insights in Alzheimer's disease. Lancet Neurol 12(1):92–104
pubmed: 23237904
doi: 10.1016/S1474-4422(12)70259-4
Tcw J, Goate AM (2017) Genetics of beta-amyloid precursor protein in Alzheimer's disease. Cold Spring Harb Perspect Med 7(6):a024539
pubmed: 28003277
pmcid: 5453386
doi: 10.1101/cshperspect.a024539
Bae B, Miura P (2020) Emerging roles for 3' UTRs in neurons. Int J Mol Sci 21(10):3413
pubmed: 32408514
pmcid: 7279237
doi: 10.3390/ijms21103413
Schuster SL, Hsieh AC (2019) The untranslated regions of mRNAs in cancer. Trends Cancer 5(4):245–262
pubmed: 30961831
pmcid: 6465068
doi: 10.1016/j.trecan.2019.02.011
Chatterjee S, Pal JK (2009) Role of 5'- and 3'-untranslated regions of mRNAs in human diseases. Biol Cell 101(5):251–262
pubmed: 19275763
doi: 10.1042/BC20080104
Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S et al (2006) Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci USA 103(18):7130–7135
pubmed: 16641106
pmcid: 1459029
doi: 10.1073/pnas.0509695103
Nagata K, Takahashi M, Matsuba Y, Okuyama-Uchimura F, Sato K, Hashimoto S et al (2018) Generation of App knock-in mice reveals deletion mutations protective against Alzheimer's disease-like pathology. Nat Commun 9(1):1800
pubmed: 29728560
pmcid: 5935712
doi: 10.1038/s41467-018-04238-0
Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B et al (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1(5):345–347
pubmed: 1302033
doi: 10.1038/ng0892-345
Gyorgy B, Loov C, Zaborowski MP, Takeda S, Kleinstiver BP, Commins C et al (2018) CRISPR/Cas9 mediated disruption of the Swedish APP allele as a therapeutic approach for early-onset Alzheimer's disease. Mol Ther Nucleic Acids 11:429–440
pubmed: 29858078
pmcid: 5992788
doi: 10.1016/j.omtn.2018.03.007
Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J et al (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49(9):1373–1384
pubmed: 28714976
pmcid: 5669039
doi: 10.1038/ng.3916
Takalo M, Wittrahm R, Wefers B, Parhizkar S, Jokivarsi K, Kuulasmaa T et al (2020) The Alzheimer's disease-associated protective Plcgamma2-P522R variant promotes immune functions. Mol Neurodegener 15(1):52
pubmed: 32917267
pmcid: 7488484
doi: 10.1186/s13024-020-00402-7
Yang A, Kantor B, Chiba-Falek O (2021) APOE: the new frontier in the development of a therapeutic target towards precision medicine in late-onset Alzheimer's. Int J Mol Sci 22(3):1244
pubmed: 33513969
pmcid: 7865856
doi: 10.3390/ijms22031244
Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME et al (2018) Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med 24(5):647–657
pubmed: 29632371
pmcid: 5948154
doi: 10.1038/s41591-018-0004-z
Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106–118
pubmed: 23296339
pmcid: 3726719
doi: 10.1038/nrneurol.2012.263
de Almada BV, de Almeida LD, Camporez D, de Moraes MV, Morelato RL, Perrone AM et al (2012) Protective effect of the APOE-e3 allele in Alzheimer's disease. Braz J Med Biol Res 45(1):8–12
pubmed: 22068907
doi: 10.1590/S0100-879X2011007500151
Delabio R, Rasmussen L, Mizumoto I, Viani GA, Chen E, Villares J et al (2014) PSEN1 and PSEN2 gene expression in Alzheimer's disease brain: a new approach. J Alzheimers Dis 42(3):757–760
pubmed: 24927704
doi: 10.3233/JAD-140033
Ortiz-Virumbrales M, Moreno CL, Kruglikov I, Marazuela P, Sproul A, Jacob S et al (2017) CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 (N141I) neurons. Acta Neuropathol Commun 5(1):77
pubmed: 29078805
pmcid: 5660456
doi: 10.1186/s40478-017-0475-z
Yan R, Vassar R (2014) Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 13(3):319–329
pubmed: 24556009
pmcid: 4086426
doi: 10.1016/S1474-4422(13)70276-X
Park H, Oh J, Shim G, Cho B, Chang Y, Kim S et al (2019) In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease. Nat Neurosci 22(4):524–528
pubmed: 30858603
doi: 10.1038/s41593-019-0352-0
He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J et al (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467(7311):95–98
pubmed: 20811458
pmcid: 2936959
doi: 10.1038/nature09325
Wong E, Liao GP, Chang JC, Xu P, Li YM, Greengard P (2019) GSAP modulates gamma-secretase specificity by inducing conformational change in PS1. Proc Natl Acad Sci USA 116(13):6385–6390
pubmed: 30850537
pmcid: 6442608
doi: 10.1073/pnas.1820160116
Lee JK, Kim NJ (2017) Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer's disease. Molecules 22(8):1287
pubmed: 28767069
pmcid: 6152076
doi: 10.3390/molecules22081287
Raikwar SP, Thangavel R, Dubova I, Selvakumar GP, Ahmed ME, Kempuraj D et al (2019) Targeted gene editing of glia maturation factor in microglia: a novel Alzheimer's disease therapeutic target. Mol Neurobiol 56(1):378–393
pubmed: 29704201
doi: 10.1007/s12035-018-1068-y
Barman NC, Khan NM, Islam M, Nain Z, Roy RK, Haque A et al (2020) CRISPR-Cas9: a promising genome editing therapeutic tool for Alzheimer's disease-a narrative review. Neurol Ther 9(2):419–434
pubmed: 33089409
pmcid: 7606404
doi: 10.1007/s40120-020-00218-z
Sun J, Carlson-Stevermer J, Das U, Shen M, Delenclos M, Snead AM et al (2019) CRISPR/Cas9 editing of APP C-terminus attenuates beta-cleavage and promotes alpha-cleavage. Nat Commun 10(1):53
pubmed: 30604771
pmcid: 6318289
doi: 10.1038/s41467-018-07971-8
Perutz MF, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 91(12):5355–5358
pubmed: 8202492
pmcid: 43993
doi: 10.1073/pnas.91.12.5355
Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C et al (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517(7536):583–588
pubmed: 25494202
doi: 10.1038/nature14136
Park H, Hwang Y, Kim J (2021) Transcriptional activation with Cas9 activator nanocomplexes rescues Alzheimer's disease pathology. Biomaterials 279:121229
pubmed: 34739981
doi: 10.1016/j.biomaterials.2021.121229